Peter C. Enzinger - Concepedia

Author

Peter C. Enzinger

Also Known As

Enzinger, Peter C., Li-Yuan Bai, P C Enzinger, P ENZINGER, P. C. Enzinger, P. Enzinger, P.C. Enzinger, Peter C Enzinger, Peter C. Enzinger, Peter C Enzinger

274

Publications

24.5K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Massachusetts General Hospital Harvard University Brigham and Women's Hospital Cornell University

About

Peter C. Enzinger is an author at Dana-Farber Cancer Institute specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	63	8.5K
2	Gastroenterology	19	26	4.9K
3	Health Sciences	12	13	2.5K
4	Public Health	1	1	24
5	Health Policy	1	1	24

Peter C. Enzinger

117

Publications

19.7K

Citations

H-Index

Page 1

	Year	Citations
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Journal of the National Comprehensive Cancer Network Gastrointestinal OncologyLocalized Gastric CancerMedicineCancer ManagementImmunology	2022	1.6K
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Jong‐Mu Sun, Lin Shen, Manish A. Shah, The Lancet Chemotherapy Versus ChemotherapyOncologyEsophageal CancerGastrointestinal OncologyClinical Trials	2021	1.5K
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology Al B. Benson, Alan P. Venook, Lynette Cederquist, Journal of the National Comprehensive Cancer Network	2017	1.4K
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Takashi Kojima, Manish A. Shah, Kei Muro, Journal of Clinical Oncology	2020	1.1K
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang, JAMA Oncology	2020	1.1K
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Journal of the National Comprehensive Cancer Network	2019	1.1K
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial Kohei Shitara, Florian Lordick, Yung‐Jue Bang, The Lancet OncologyEsophageal CancerGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaGastroenterology	2023	609
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors Matthew H. Kulke, Keith Stuart, Peter C. Enzinger, Journal of Clinical Oncology	2006	512
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus Manish A. Shah, Takashi Kojima, Daniel Hochhauser, JAMA Oncology	2018	511
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study Andrew X. Zhu, Dushyant V. Sahani, Dan G. Duda, Journal of Clinical Oncology	2009	473

Page 1